Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,716,000 ordinary shares.
- Repurchase Price: 1,321.1706 pence per share.
- Treasury Shares Held: 410,333,158 shares (representing 7.30% of total voting rights).
- Shares in Issue: 5,613,744,809 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury shareholding following the September 26 transaction. The total number of shares held in Treasury now represents 7.30% of the total voting rights in the Company. The number of shares in issue remains 5,613,744,809, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,613,744,809) for accurate calculation of ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (410,333,158) and its impact on the total voting rights percentage (7.30%).
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim reports for revenue and profit metrics.